AQ Enigma is AQ Biotech’s service delivery platform for biomarker discovery and pharmaceutical research. We use phage-biosensors to study urine, serum and saliva for potential early signals of disease.
AQ Enigma is AQ Biotech’s service delivery platform for biomarker discovery and for conducting pharmaceutical research. We use phage-biosensor signals to compare samples, with a focus on oncology, neurodegenerative disease, infectious disease and changes in protein structures.
Collaboration
Who it’s for
Research question
Biomarker Discovery and De Novo Target
Diagnostic and Pharma R&D
Which unknown biomarkers emerge from rich and complex clinical cohorts without prior target knowledge?
Protein Structural Validation
Protein research, AI drug discovery, companies Pharma R&D
Protein analysis, how does a computationally designed protein or target behave in real solution, and structural analysis.
Joint experiments
Clinicians, academic investigators & translational research teams
How does a target protein change conformation upon ligand binding, modification, or mutation?
Focused studies
Diagnostics and Pharma clinical R&D teams
How accurately can we stratify defined patient cohorts (e.g., responders vs. non-responders, healthy vs. disease) directly from unprocessed urine, serum, or saliva?
Have a research question you would like us to tackle?
Tell us what you are working on and where you could use our help.
Phage-biosensors convert interactions with molecules in a sample into measurable signals. AQ Biotech studies these signals to look for patterns that may be associated with disease.
Our projects
Explore the research underway across our pipeline.
Advantages of phage-biosensors
Non-invasive sampling
Urine and saliva can be collected without an invasive procedure. Sample choice depends on the study.
Multi-omics
Sensor readings can be studied alongside other molecular measurements.
Specificity
Researchers can study which targets or sample conditions produce different sensor responses.
Scalability
Instrument-based readouts offer a consistent format for comparing signals across samples.
Kidney diseases
The Nanjing project studies biosensor signals associated with kidney disease. Sample collection is underway.
Study focus
The study explores whether patterns across biosensor readings can help identify candidate signals for kidney disease research.
Research collaborators
The project involves Jiangsu Public Hospital and KingMed Diagnostics.
Parkinson’s disease
Phage-biosensors developed in Turku, Finland, were selected for testing in a larger, independent cohort in Chengdu, China.
Study question
The study asks whether biosensor signals in urine and serum differ between Parkinson’s disease, other neurological conditions and healthy controls.
Turku, Finland
Finnish cohort
The study compared samples from different stages of Parkinson’s disease with samples from other neurological conditions and healthy controls. Candidate sensors were selected for further testing.
Chengdu, China
Chinese cohort
The Chinese cohort adds conditions that can be difficult to distinguish from Parkinson’s disease, such as multiple system atrophy. Testing covers both urine and serum, and new sensors are developed for each sample type.
Lung cancer
The lung cancer project investigates biosensor signals associated with lung cancer. The research involves teams in Shanghai and Chengdu.
Research teams
The project involves the Shanghai Public Health Clinical Center and West China Hospital.
Planned milestones
The research and assay validation report is planned for December 2026. The clinical validation phase is scheduled to start in January 2027.
Prostate cancer
The research develops urine-based biosensors for prostate cancer detection. Biosensor signals were studied in Finland using samples from Helsinki University Hospital. Selected biosensor candidates were taken forward to pre-clinical validation in a Chinese cohort at Jiangsu Cancer Hospital in Nanjing.
Research milestone
The team reported on the project in September 2026.
Next step
AQ is seeking a partner for the next stage of the project.
Metastatic cancers
The research focuses on detecting different metastatic cancers from urine samples. The sample collection and research is being conducted in Turku and Nanjing.
Research teams
Turku University Hospital and Jiangsu Cancer Hospital participate in the study.
Research focus
The study looks for patterns across sensor readings that may be associated with metastatic cancer.
Organ transplantation
The current research focuses on studying phage-biosensor signals associated with chronic lung allograft dysfunction (CLAD) and non-CLAD after lung transplantation, using urine, saliva and plasma samples.
Study question
The study asks whether biosensor readings can reveal patterns associated with rejection in lung transplant recipients.
Research status
The study with Baylor St. Luke’s Medical Center is ongoing.
Tuberculosis
The project studies biosensor signals associated with tuberculosis in collaboration with the Shanghai Public Health Clinical Center.
Study focus
The study explores whether biosensor readings can reveal patterns associated with tuberculosis.
Planned milestones
The research and assay validation report is planned for December 2026. The clinical validation phase is scheduled to start in January 2027.
Sepsis
The sepsis project studies disease-associated biosensor signals at Max Nanavati Hospital in Mumbai.
Study focus
The study explores patterns across biosensor readings that may be associated with sepsis.
Project stage
The project is in the research and assay validation phase, with a milestone scheduled for December 2026.
AQ Enigma technology
Can a protein have a fingerprint?
Some sensors may respond more strongly to a protein than others. Put the readings in order and the pattern becomes a fingerprint.
One protein, several forms
Switch states to compare the patterns. Select a bar to see its reading.
Simulated reading (0–100)S1 · 74
State A: S1 and S5 give stronger signals.State B: S2 and S4 rise, while S1 and S5 fall.
Why look at a group of readings?
A single reading tells you how one sensor responded. Together, the readings show which signals shift as the protein changes state and which stay steady.
AQ Enigma studies protein responses using biosensors developed from bacteriophages.
Biomarker discovery
Biomarker discovery with phage-biosensors
A biomarker is a measurable indicator of a biological state. Discovery starts by finding candidates and asking whether they are linked to the change you care about.
Researchers use phage-biosensors to look for signals linked to a disease or biological state. AQ Enigma brings together readings from selected protein biosensors to compare proteins and examine how their signals change across states.
AQ Enigma research
Research evidence
Explore the protein-state experiments, sensor library, and comparison with predicted protein structures.
Transferrin experiment
How does the signal differ with and without iron?
Transferrin carries iron in the blood. This experiment compares its sensor readings in the iron-bound and iron-free states.
Solid orange: iron-free
Solid blue: iron-bound
At all three time points shown in this experiment, the iron-free form gave higher readings. This gives researchers a concrete example of comparing two states of the same protein. The dashed lines show the comparison after heat denaturation.
How does glucose binding change the signal?
Concanavalin A is a protein that binds sugars. A glucose experiment compared two states. The chart shows a lower signal when the binding site was occupied than when it was free, giving the team another example of how binding can affect the readout.
Sensor library
How a panel forms a fingerprint
The same protein can give different readings across sensors. A panel lets researchers ask whether similarly shaped proteins leave similar patterns.
Five protein structure groups of interest
Mostly alpha-helical globular proteins
Mostly beta-sheet globular proteins
Globular proteins with both alpha helices and beta sheets
Fibrous or rod-like proteins
Multidomain signaling proteins
Alpha helices and beta sheets are two common ways a protein chain folds.
Proteins on the Enigma research list
38 entries · October 2026
Fibrinogen
Aldolase
Transferrin
Alpha-amylase
Alcohol dehydrogenase
Peroxidase
Insulin
Tyrosine kinase
Albumin
Carbonic anhydrase
Alkaline phosphatase
Papain
Hemoglobin
Phytohemagglutinin
Calprotectin
DNase I
Benzonase
KIM-1
NGAL
hEGF
Ferritin
Streptavidin
Neuraminidase
PSA
Kallikrein
Lactoferrin
Pepsin
D-lactate dehydrogenase
Beta-galactosidase
GFP
CRP
NF-κB
Lysozyme
Concanavalin A
Cytochrome C
Catalase
Ribonuclease A
Proteinase K
Structural comparison
How do the signals compare with AlphaFold predictions?
Researchers used AlphaFold’s predicted structures to ask whether sensor signals vary with the distance between parts of a protein.
The horizontal axis shows the predicted distance between domains. The vertical axis shows the relative sensor response. Both trend lines rise in this set of proteins, so larger predicted distances tended to go with higher readings.
A next research question is whether this relationship holds across more proteins.
Research progress since July 2026
Experimental findings
Protein fingerprinting
Proof-of-principle experiments showed different sensor readings for different states of the same protein.
Protein surface features
The team is studying what biosensor responses can reveal about protein surfaces alongside AlphaFold predictions.
Structural comparison
The team reports reproducing correlations between biosensor readings and AlphaFold predictions. Higher-resolution analysis is underway.
Ongoing research
Patient sample pilot
Pilot testing uses patient samples to explore whether sensor readings can characterize protein profiles.
Functional assays
The team is assessing AQ Enigma in functional assays using medically relevant targets and receptor-binding models.
Do you want to challenge us with your research problems?
Compare two states of one proteinDoes the sensor pattern change when a molecule binds to a protein?
Compare structurally similar proteinsDo structurally similar proteins produce similar signals?
Struggling to identify a biomarker?Tell us about the samples or cohorts you want to study.
AQ Biotech
We develop biosensors for biomarker discovery. AQ Enigma is the platform we use to study and compare signals from proteins.
AQ Biotech Signs Strategic Framework Agreement with Nanjing KingMed Medical Laboratory and Launches First Joint Kidney Disease Project with Jiangsu Province Hospital
November 13, 2026 – AQ Biotech Oy has entered into a strategic Cooperation Framework Agreement with Nanjing KingMed Medical Laboratory (Part of KingMed Diagnostics Group). Simultaneously, the two companies have signed a tripartite Cooperation Agreement together with Jiangsu Province Hospital to launch their first joint research project focused on kidney disease classification and biomarker discovery.
Today AQ Biotech and Nanjing KingMed Medical Laboratory have signed a Framework agreement for scientific research, methodological validation, and clinical translation to develop early screening and disease monitoring solutions in the Chinese market. Nanjing KingMed Medical Laboratory brings extensive clinical and operational capabilities in acting as a strategic partner connecting AQ Biotech’s non-invasive phage-biosensor platform with top-tier Chinese medical institutions.
Signing of the cooperation framework agreement between AQ Biotech and Nanjing KingMed Medical Laboratory.
First Joint Milestone: Non-Invasive Kidney Disease Diagnostics
Building immediately on this strategic partnership, AQ Biotech, Nanjing KingMed Medical Laboratory and the Department of Nephrology at Jiangsu Province Hospital—led by Principal Investigator Prof Yuan Yanggang—have defined and initiated their first joint project.
Representatives from AQ Biotech and the Department of Nephrology at Jiangsu Province Hospital.
While AQ Biotech’s phage-biosensor platform has already demonstrated strong clinical potential across oncology, neurological, and infectious diseases in Finland and China, this marks the company's first dedicated initiative in nephrology. The project focuses on non-invasive kidney disease classification and biomarker discovery, with the long-term goal of advancing toward larger-scale clinical validation and commercial In Vitro Diagnostic (IVD) solutions.
Executive Perspectives
“Partnering with Nanjing KingMed Medical Laboratory is a major milestone in our global expansion strategy. With their unmatched diagnostic infrastructure and clinical reach, KingMed is the best partner to scale our phage-biosensor technology to commercial scale. Defining our very first joint project right out of the gate with a national clinical leader like Jiangsu Province Hospital demonstrates the speed and shared ambition of this collaboration.”
— Jukka Holappa, Chief Business Officer, AQ Biotech Oy
“AQ Biotech’s non-invasive, antibody-free phage-biosensor technology represents a highly promising approach to multi-omics biomarker discovery. By combining AQ Biotech’s innovative platform with KingMed’s operational scale and the renowned clinical expertise of Jiangsu Province Hospital, we aim to unlock new, non-invasive diagnostic tools that address critical unmet clinical needs in kidney diseases.”
— Mao Yuan, Vice General Manager, Nanjing KingMed Medical Laboratory Co
About Nanjing KingMed Medical Laboratory
Nanjing KingMed Medical Laboratory Co is located in Nanjing and it is part of KingMed Diagnostics, a leading independent clinical laboratory (ICL) and third-party medical diagnostic service provider in China. It offers comprehensive clinical testing, pathology, and precision medicine services across a nationwide network.
About Jiangsu Province Hospital
Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) is a premier Class 3A hospital. Its Department of Nephrology is recognized as a national key clinical specialty with extensive expertise in kidney disease diagnosis, renal pathology, and clinical cohort management.
2026年11月13日——AQ Biotech Oy 与南京金域医学检验实验室(金域医学集团旗下机构)签署战略合作框架协议。双方同时与江苏省人民医院签署三方合作协议,启动首个聚焦肾脏疾病分类和生物标志物发现的联合研究项目。
AQ Biotech 与南京金域医学检验实验室签署框架协议,将开展科学研究、方法学验证和临床转化,为中国市场开发疾病早筛和监测方案。南京金域凭借丰富的临床与运营经验,作为战略合作伙伴,将 AQ Biotech 的无创噬菌体生物传感器平台与中国领先的医疗机构对接。
From Turku to Chengdu: Raakel’s First Visit to China
Raakel Lehmusmäki, Application Scientist at AQ Biotech Oy in Turku, Finland, embarked on her first trip to China with a three-week visit at Chengdu. This visit provided a unique opportunity to collaborate directly with international colleagues and also to meet local professors and share best practices from Finland.
Anticipating the trip, she was keen to experience Chengdu's natural surroundings, but her primary goal was to engage with new teammates and advance her research within a fresh scientific and cultural setting.
When asked what she had been looking forward to prior to the trip, she mentioned Chengdu's natural scenery, but above all, the opportunity to meet new colleagues and continue her research in a different cultural and scientific environment.
“I was excited to do the same research that we’re doing in Turku, but in a completely different environment, and to challenge myself with a new culture.”
Research in a New Environment
As an Application Scientist, Raakel's work covers biosensor development, experimental testing, and data analysis. She has also been gaining experience in sequencing technologies and contributing to the biomarker discovery.
During her visit to Chengdu, one of her main responsibilities was to support and guide the local team in their research activities, including biosensor development and testing, coordinating experiments, and managing project progress. The visit also gave her an opportunity to learn more about the research environment and ongoing projects at Chengdu Future Medical City.
A key part of her work involved testing biosensors previously developed in Finland using a larger research cohort in Chengdu, while also exploring the development of new biosensors for Parkinson's disease research.
Figure 1. Raakel working with a colleague in the laboratory in Chengdu.
Compared with the samples available in Finland, the research cohort in Chengdu is much larger and includes a wider range of disease classifications with detailed metadata. This allows researchers to conduct more comprehensive analyses and comparisons, potentially identifying differences that may not have been apparent in smaller sample sets.
For Raakel, the visit was also an opportunity to share the Finnish team's research experience with colleagues in Chengdu and contribute to their ongoing work.
Working Together Across Cultures
This was also Raakel's first experience managing a project with a team from another country.
“The first step is getting to know the people, understanding their strengths, and making sure we use those strengths to our advantage while building a well-structured project plan.”
Working with colleagues from different cultural and professional backgrounds required her to get to know the team, coordinate responsibilities, and establish a clear project plan. By understanding each person's strengths, she aimed to help the team work effectively and make the most of their individual expertise.
Figure 2. Raakel conducting laboratory work alongside colleagues in Chengdu.
What stood out to her, however, was not the challenge of working across cultures, but the atmosphere within the Chengdu team.
“I really like the team. Everyone is hard-working, yet still relaxed. We’re having a lot of fun.”
When asked about the most interesting part of her visit, Raakel did not immediately point to the experiments or research facilities. Instead, she spoke about the people she had met.
“The most interesting part has been getting to know the people and their backgrounds. It’s really interesting to hear what kind of research is being done in the Future City of Medicine.”
Figure 3. Raakel with colleagues in Chengdu.
A Research Visit and a New Experience
Chengdu was the first city Raakel visited in China. Before arriving, she had been looking forward to seeing the city’s natural surroundings. Despite being far from home, she found something familiar about the city.
“I really like it so far. It reminds me of Finland a little bit,” Raakel said.
Beyond her research work, Raakel also spent time exploring Chengdu with colleagues from AQ’s Chengdu team. They visited the giant pandas together and shared a Sichuan hotpot dinner, which Raakel really enjoyed.
As a keen tennis player, Raakel visited Sichuan University, where she walked around the campus and played tennis on the university courts.
Advancing Research
The visit enabled Raakel to discuss research progress directly with her colleagues in China, share technical experience from the Finnish team, and support laboratory activities and project management in Chengdu.
The larger research cohort in Chengdu provides opportunities for further testing of existing biosensors, as well as for developing new biosensors related to Parkinson's disease research.
Through this visit, AQ Biotech's teams in Finland and Chengdu have strengthened their day-to-day research collaboration. Looking ahead, AQ Biotech will continue to build on the expertise of its teams across different locations, advance the development and validation of biosensor technologies, and explore their potential applications in early disease detection.
“I really enjoyed my time in Chengdu. It was nice to meet everyone and work with the team, and I already miss it a little,” Raakel shared.
As the research collaboration continues, there is much to look forward to, including the possibility of welcoming Raakel back to Chengdu and bringing the teams together again.
在芬兰图尔库的 AQ Biotech Oy 担任应用科学家的 Raakel Lehmusmäki 首次来到中国,在成都进行了为期三周的访问。此行让她有机会与海外同事面对面合作,拜访当地教授,并分享芬兰团队积累的实践经验。
AQ Biotech Closes €2.5 Million Seed Funding Round – Targeting on China Expansion and Next-Generation Biomarker Discovery
AQ Biotech announced that it had raised €2.5 million in seed funding, combining private equity investment with support from Business Finland. The funding is intended to expand operations in Hong Kong and mainland China, support targeted hiring, and build biomarker discovery capacity in Turku and Hong Kong.
The announcement also noted research funding from China’s Ministry of Science and Technology and Jiangsu provincial R&D programs. Those projects support evaluation of the company’s phage-biosensor method in disease areas including tuberculosis and prostate cancer.
Business Finland senior advisor Tuomas Planman highlighted the company’s research network and export potential. AQ Biotech said it planned to extend capabilities from its Turku laboratory to Hong Kong and work with joint venture partners in Chengdu and Nanjing as it prepared for a future Series A round.
Accelerating Next Generation of Biotech Innovation: AQ Biotech Summer School Executed Successfully in Chengdu
AQ Biotech and YiAi Biotech organized a two-week summer school at Tianfu Jincheng Lab in Chengdu’s City of Future Medicine, with support from COICC. The program introduced early-career bioscientists to AQ Biotech’s phage-biosensor research.
The opening program included speakers from West China Hospital and Shanghai Jiao Tong University, along with a remote greeting from the Finnish Embassy in Beijing. The sessions brought together scientific, clinical and business perspectives.
Photo from the AQ Biotech Summer School in Chengdu.
Six participants were selected through interviews. All six passed their final assessments and received AQ Biotech certificates. The company described the program as a way to prepare local researchers to contribute to projects in Chengdu and Nanjing.
AQ Biotech Chengdu Ltd: New Joint Venture to Advance Early Detection of Neurological Diseases
On May 14, 2026, AQ Biotech Oy and Sichuan Yiaijinxuan Technology Co., Ltd. signed an agreement to establish AQ Biotech Chengdu Ltd. The joint venture builds on work that began in September 2025 with West China Hospital of Sichuan University on non-invasive approaches to detecting Parkinson’s disease.
Tang Lin and Timo Teimonen at the Chengdu signing ceremony.
Valtteri Kaasinen, a professor of neurology at Turku University Hospital, is continuing as a principal scientist alongside the AQ Biotech and West China Hospital teams. AQ Biotech reported a positive funding decision from Business Finland after the partners applied through the joint call with China’s Ministry of Science and Technology.
The research aims to develop a method for earlier detection of Parkinson’s disease. At the time of the announcement, the partners were setting up a laboratory in Chengdu and preparing to hire a local research team.
AQ Biotech Signs an Agreement with OG Pharmaceuticals to Establish New Joint Venture in Nanjing
AQ Biotech Oy and OG Pharmaceuticals signed an agreement on May 8, 2026 to establish AQ Biotech Nanjing Ltd. The partners had been working together since May 2022 to evaluate AQ Biotech’s non-invasive, antibody-free phage-biosensor method for prostate cancer detection in China.
Wangzhou Zhao and Timo Teimonen at the Nanjing signing ceremony.
The venture is intended to develop early detection applications for prostate and other urinary tract cancers. Under the announced agreement, AQ Biotech Global retains ownership of its global intellectual property and know-how, while the venture receives exclusive rights for cancer detection applications in the Chinese market.
Jiangsu Cancer Hospital is a clinical research partner. The collaboration brings together AQ Biotech’s technology, the hospital’s clinical expertise, and access to patient cohorts for work on earlier prostate cancer detection.